Advent International, a private equity firm, is investing an undisclosed amount into Iodine boosting its valuation beyond $1 billion. The hope is that the company’s AI-powered clinical documentation improvement software can capture a greater share of the market for software products that help hospitals code and bill accurately to receive reimbursement.
